Investment Rating - The investment rating for the company is "Buy" with a maintained rating for the next six months [7]. Core Views - The company has shown steady revenue growth, with a 11.02% year-on-year increase in revenue to 3.051 billion RMB in the first half of 2025, and a 10.74% increase in net profit to 818 million RMB [1]. - The company is actively expanding its business through acquisitions, including a 70% stake in Dongfeng Majiji Pharmaceutical and an 80% stake in Inner Mongolia Alashan Congrong Group, which will enhance its product portfolio [4]. - The company has improved its cash flow, with a net cash flow from operating activities of 9.65 billion RMB in the first half of 2025, indicating a shift towards high-quality development [3]. Financial Performance - In the first half of 2025, the core product, Ejiao and its series, generated revenue of 2.845 billion RMB, reflecting a growth of 11.50% year-on-year, with a gross margin of 74.83% [2]. - The company’s cash reserves are robust, with a cash and cash equivalents balance of 4.004 billion RMB at the end of the period [3]. - The revenue forecast for 2025-2026 has been slightly adjusted to 67.81 billion RMB and 77.85 billion RMB respectively, with net profit estimates raised to 17.94 billion RMB and 20.66 billion RMB for the same periods [5]. Valuation Metrics - The company’s earnings per share (EPS) is projected to be 2.79 RMB in 2025, with a price-to-earnings (P/E) ratio of 16.81 [5]. - The projected revenue growth rates for 2025 and 2026 are 14.53% and 14.81% respectively, indicating a stable growth trajectory [5]. - The company maintains a low debt-to-asset ratio of 19.17%, reflecting a strong balance sheet [7].

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company has shown continuous rapid growth, with a 44.50% year-on-year increase in revenue for the first half of 2025, reaching 1.886 billion yuan, and a 151.38% increase in net profit attributable to shareholders, amounting to 84 million yuan [1] - The demand for the company's products is driven by the intelligent connected vehicle and edge AI hardware sectors, contributing to strong revenue growth [2] - The overall gross margin for the first half of 2025 is 13.36%, a decrease of 3.23 percentage points year-on-year, primarily due to the product mix and increased sales of lower-margin products [3] - The company has expanded its edge AI capabilities across multiple application scenarios, including drones, AR glasses, robots, and AI companions, showcasing its technological advancements [4][5] Financial Performance - In the first half of 2025, domestic revenue reached 1.354 billion yuan, up 56.50% year-on-year, while overseas revenue was 532 million yuan, a 20.93% increase [2] - The second quarter of 2025 saw revenue of 889 million yuan, a 21.65% year-on-year increase but a 10.8% quarter-on-quarter decline, mainly due to fluctuations in domestic revenue [2] - The company has adjusted its net profit forecasts for 2025-2027 to 210 million, 300 million, and 410 million yuan respectively, with corresponding PE ratios of 61, 42, and 31 times [6] Market Position and Future Outlook - The company is positioned in the communication and communication equipment industry, with a target price yet to be specified [6] - The company is expected to improve its profitability in the second half of 2025, despite current pressures on gross margins [3] - The ongoing development of edge AI applications is anticipated to open up significant growth opportunities for the company in the future [4][5]

固定收益 | 固定收益专题 刘昱云 分析师 SAC 执业证书编号：S1110525070010 liuyuyun@tfzq.com 唐海清 分析师 SAC 执业证书编号：S1110517030002 tanghaiqing@tfzq.com 何楠飞 分析师 SAC 执业证书编号：S1110525070004 henanfei@tfzq.com 近期报告 1 《固定收益：信用票息仍占优-信用 策略周报 20250921》 2025-09-22 2 《固定收益：固收点评-债市定价， 谁在主导？》 2025-09-21 3 《固定收益：股债之间-利率专题》 2025-09-21 利率专题 证券研究报告 再论国债买卖与降息 1、国债买卖：悬念等待揭晓 2025 年 09 月 23 日 作者 谭逸鸣 分析师 SAC 执业证书编号：S1110525050005 tanyiming@tfzq.com 预期"升温"：（1）9/3，财政部与央行联合工作组召开会议，双方就央行 国债买卖操等议题进行了深入研讨，使得工具重启的预期进一步发酵；（2） 债市调整行情下市场的期待愈发升温，当下不论是长端、超长端的绝对点 位，还是二者相对利 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price not specified [6][18]. Core Views - The company achieved a revenue of 2.496 billion yuan in the first half of 2025, representing a year-on-year growth of 15.31%, while the net profit attributable to the parent company was 882 million yuan, down 8.73% year-on-year [1]. - The company is expected to accelerate its performance in the second half of the year due to a strong delivery schedule and existing customer orders, with significant contributions anticipated from new data centers in Pinghu, Foshan, and Huizhou [2]. - The company has successfully delivered approximately 220MW of computing centers in key regions, achieving a historical high in delivery scale, and has made significant advancements in the size of individual data centers [3]. - The company is a leader in liquid cooling, IDC, and AIDC, having established a comprehensive framework for integrated computing centers across the country, with a significant number of intelligent computing centers and cabinet resources [4]. - The company has ample cash resources, totaling 5.49 billion yuan as of the first half of 2025, which will support horizontal mergers and acquisitions to enhance market share and industry concentration [5]. Financial Summary - The company adjusted its profit forecast for 2025 and 2026, estimating net profits of 2.4 billion yuan and 3.2 billion yuan respectively, with corresponding PE ratios of 36 and 27 times [6]. - The company reported a gross margin under pressure, but the overall development of data centers and intelligent computing centers is progressing rapidly, with expectations for positive impacts on profits from accelerated deliveries in the second half of the year [6]. - The company’s total assets are projected to grow from 23.31 billion yuan in 2023 to 37.28 billion yuan by 2027, indicating a strong growth trajectory [13].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 23.02 CNY [7]. Core Views - The company has demonstrated strong growth in EBITDA and has significant expansion capabilities, particularly in the IDC sector, benefiting from high demand in the AI era [2][6]. - Despite a decline in revenue in Q2, the overall growth momentum in the IDC services is expected to rebound in the second half of the year [3][5]. Financial Performance - For the first half of 2025, the company reported revenue of 1.148 billion CNY, a year-on-year increase of 8.20%, and a net profit attributable to the parent company of 87.89 million CNY, up 16.09% [1]. - The IDC service revenue reached 895 million CNY in the first half of 2025, reflecting a year-on-year growth of 42.22%, with EBITDA increasing by 50.87% to 594 million CNY [2]. - The company’s Q2 revenue was 612 million CNY, a year-on-year decrease of 9.97%, while net profit for the same period was 36 million CNY, up 43.37% [3]. Expansion and Assets - As of June 2025, the company operates 14 self-built data centers across various cities, with over 57,000 operational cabinets and ongoing large-scale data center projects [4]. - Fixed assets reached 7.88 billion CNY, up from 6.28 billion CNY the previous year, indicating robust expansion capabilities [4]. Profitability Metrics - The gross margin for the first half of 2025 was 33.49%, with Q2 gross margin at 35.17%, showing a continuous upward trend [5]. - The report anticipates that as the overall cabinet utilization rate improves, both revenue and profits will continue to grow significantly [5]. Earnings Forecast - The company is projected to achieve net profits of 200 million CNY, 288 million CNY, and 412 million CNY for the years 2025, 2026, and 2027, respectively, with corresponding PE ratios of 113, 79, and 55 [6].

Investment Rating - The report assigns a "Buy" rating for the company with a target price of 69.02 CNY, based on a current price of 56.09 CNY [5]. Core Insights - The company is a leading player in the data storage controller chip and AIoT signal processing chip sectors, benefiting from high barriers to entry and a robust growth trajectory driven by high-margin products and recovering downstream demand [1][4]. - The company achieved a revenue of 1.174 billion CNY in 2024, representing a year-over-year growth of 13.55%, and a net profit of 118 million CNY, reflecting a significant increase of 126% [1][24]. - The AIoT chip business saw a remarkable revenue growth of 73.61% in 2024, reaching 251 million CNY, indicating strong demand in emerging applications [3][4]. Financial Data and Valuation - The company is expected to generate revenues of 1.353 billion CNY in 2025, 1.671 billion CNY in 2026, and 2.066 billion CNY in 2027, with net profits projected at 124 million CNY, 171 million CNY, and 238 million CNY respectively [4]. - The company maintains a high R&D expense ratio of 36%-38%, with R&D expenditures reaching 425 million CNY in 2024 [3][34]. - The gross profit margin improved to 47.47% in 2024, up from 35.43% in 2019, showcasing enhanced profitability [33]. Industry Analysis - The global storage chip market is projected to grow significantly, with an estimated size of 129.77 billion USD in 2024, driven by demand from AI, 5G, and automotive sectors [43]. - The company holds a 25% market share in the global independent third-party SSD controller chip market, with a shipment volume of 49 million units in 2024 [2][55]. - The AIoT industry is expanding rapidly, with the number of connected IoT devices expected to reach 25 billion by 2025, creating substantial demand for AIoT chips [60][62].

Investment Rating - The investment rating for the company is "Accumulate" [7] Core Views - The company reported a significant increase in performance for the first half of 2025, with operating revenue reaching 11.546 billion yuan, a year-on-year growth of 39.98%, and a net profit attributable to shareholders of 471 million yuan, up 125.03% year-on-year [1] - The overall IoT industry remains in a high-growth state, with the company achieving a 47.28% year-on-year increase in Q2 revenue [2] - The company's profitability has improved, with a gross margin of 17.71% and a net margin of 4.06%, reflecting effective cost control and management [3] - The company is actively expanding its AI and automotive sectors, integrating AI capabilities into its products and enhancing its automotive technology ecosystem [4] Financial Performance - For the first half of 2025, the company achieved a gross margin of 17.71% and a net margin of 4.06%, with year-on-year changes of -0.43 percentage points and +1.59 percentage points respectively [3] - The company's overseas revenue for the first half of 2025 reached 6.293 billion yuan, accounting for 54.50% of total revenue [2] - The company has adjusted its profit forecasts for 2025 and 2026, expecting net profits of 880 million yuan and 1.147 billion yuan respectively, with a corresponding PE ratio of 30 and 23 times [5] Future Growth Drivers - The company is focusing on AI integration across its product lines, including smart modules for AR glasses and sports cameras, and has launched an upgraded AI robot solution [4] - In the automotive sector, the company has expanded its product offerings and has successfully implemented solutions with over 20 major manufacturers [4]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [6][17]. Core Views - The company achieved a revenue of 3.711 billion yuan in the first half of 2025, representing a year-on-year increase of 9.00%, while the net profit attributable to shareholders was 320 million yuan, down 2.02% year-on-year [1]. - The urban operation segment saw a revenue of 3.186 billion yuan in the first half of 2025, growing by 11.17% year-on-year, with a gross margin of 25.91%, a decrease of 1.81 percentage points [2]. - The company secured 25 new projects in the first half of 2025, leading the industry with a new contract amount of 10.367 billion yuan, a significant year-on-year increase of 93.08% [2]. - The company is expanding its robotics segment through a strategic partnership with Shanghai Zhiyuan Robotics, which includes an investment in its subsidiary, Yushui Intelligent [3]. Financial Summary - As of June 30, 2025, the total accounts receivable amounted to 4.5 billion yuan, an increase of 300 million yuan compared to the end of 2024, with a credit impairment loss of 52 million yuan recognized in the first half of 2025, up 15 million yuan year-on-year [4]. - The forecasted net profit attributable to shareholders for 2025-2027 is projected to be 648 million, 717 million, and 803 million yuan, respectively, with year-on-year growth rates of 12.58%, 10.62%, and 12.04% [4]. - The diluted EPS for the same period is expected to be 1.63, 1.80, and 2.01 yuan, with corresponding P/E ratios of 17.51, 15.83, and 14.13 times as of September 23 [4][11]. Key Financial Metrics - The company’s total revenue is projected to grow from 6.161 billion yuan in 2023 to 10.177 billion yuan in 2027, with a compound annual growth rate of approximately 9.82% [11]. - The gross margin is expected to stabilize around 23.20% by 2027, while the net profit margin is projected to be approximately 7.89% [12]. - The company’s asset-liability ratio is forecasted to be 47.70% by 2027, indicating a stable financial structure [12].

Investment Rating - The report maintains an "Accumulate" rating for the company [6] Core Views - The company has shown significant recovery in profit growth in Q2, with a revenue of 1.64 billion yuan, representing a year-on-year increase of 69.67%, and a net profit of 168 million yuan, up 37.98% year-on-year [2] - The company is positioned well in the AI era, with strong growth potential in liquid cooling solutions, driven by increasing demand for data centers and high-power cooling needs [4] - The company has established strong domestic partnerships with major clients like Tencent and Alibaba, and is gradually making inroads into overseas markets, including a recent collaboration with Intel [5] Financial Performance - In the first half of 2025, the company achieved a revenue of 2.573 billion yuan, a 50.25% increase year-on-year, and a net profit of 216 million yuan, up 17.54% year-on-year [1] - The company's gross margin for the first half of 2025 was 26.15%, a decrease of 4.84 percentage points year-on-year, attributed to intense domestic competition and changes in product structure [3] - The company expects improvements in profitability as overseas and liquid cooling products continue to gain traction [3] Business Segmentation - Revenue from data center cooling products reached 1.351 billion yuan, up 57.91% year-on-year, driven by robust demand in data center construction [2] - Revenue from cabinet cooling products was 926 million yuan, a 32.02% increase, largely benefiting from the growth in energy storage applications [2] - The company reported a decline in revenue from bus air conditioning and rail transit air conditioning services, with revenues of 19.36 million yuan and 23.90 million yuan, down 29.81% and 50.09% year-on-year, respectively [2] Future Outlook - The company is expected to benefit from the AI wave and the increasing penetration of liquid cooling solutions, with adjusted net profit forecasts of 610 million yuan and 1.04 billion yuan for 2025 and 2026, respectively [6] - The company has a comprehensive liquid cooling solution that has gained customer trust, with cumulative deliveries reaching 1.2 GW by March 2025 [4]

Industry Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The Chinese innovative drug industry has established a trend towards global commercialization, supported by a pyramid structure of leading and quality enterprises, indicating strong sustainability in industry development [2]. - The underlying logic of the current cycle is that Chinese innovative drugs possess global competitiveness, shifting from domestic sales to international licensing and commercialization, thus opening up commercial space and maturing the ecosystem [2]. - The focus on differentiated mechanisms or high clinical value "good molecules" remains a core interest for international buyers, with early data being crucial for entering licensing windows [2]. Current Situation - The Chinese innovative drug industry is entering a phase of realization, driven by support from capital markets, policies, and talent [3]. - The industry has developed self-sustaining capabilities through business development (BD) licensing and drug commercialization [3]. - Comprehensive policy support for "true innovation" has been established, enhancing the industry's growth [3]. Future Outlook - Continued collaboration among academia, industry, and research will enhance the output of first-in-class (FIC) molecules, with China becoming one of the most efficient countries in the drug development pathway [4]. - Higher innovation levels are expected to further unlock commercial value, indicating a promising future for the industry [4]. Investment Recommendations - Focus on global blockbuster products: companies such as BeiGene, Kelun-Biotech, Innovent Biologics, and others are highlighted as key players [5]. - Attention to global best-in-class (BIC) potential companies, including EdiGene, Zai Lab, and others, is recommended [5]. - Domestic blockbuster products and asset values of companies like Hengrui Medicine and others are also suggested for consideration [5].